Nuclear fusion and medical isotope developer Shine has received marketing authorization from the European Medicines Agency (EMA) for Ilumira, its non-carrier–added lutetium-177 (Lu-177) radiopharmaceutical precursor.
Ilumira is produced at SHINE's Cassiopeia facility in Janesville, WI. The authorization opens the European Union market for the product's use in targeted radioligand therapy development, the company said.
The EMA approval follows several recent milestones for the firm, including a $240 million Series E financing round closed in February, a $263 million conditional loan commitment from the U.S. Department of Energy in April to complete its Chrysalis isotope production facility, and the January acquisition of a U.S. isotope manufacturing and distribution operation, the company noted.
